IMMUNOTHERAPY OF CANCER USING GENETICALLY ENGINEERED GD2-SPECIFIC T CELLS

• US 20140004132A1
• Filed: 09/08/2011
• Published: 01/02/2014
• Est. Priority Date: 09/08/2010
• Status: Active Grant

• Current Assignee: Baylor College of Medicine (Baylor College)
• Original Assignee: Baylor College of Medicine (Baylor College)
• Inventors: Dotti, Gianpietro, Ahmed, Nabil, Gottschalk, Stephen M.G., Grada, Zakaria, Brenner, Malcolm, Rossig, Claudia
• Granted Patent: US 9,493,740 B2
• Time in Patent Office: Days
• US Class Current: 424/178.1
• CPC Class Codes: A61K 2239/55 Lung
• CPC Class Codes: A61K 2239/57 Skin; melanoma
• CPC Class Codes: A61K 39/4611 T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
• CPC Class Codes: A61K 39/4631 Chimeric Antigen Receptors [CAR]
• CPC Class Codes: A61K 39/464471 Gangliosides, e.g. GM2, GD2 or GD3
• CPC Class Codes: A61K 39/464486 MAGE
• CPC Class Codes: A61K 39/464491 Melan-A/MART
• CPC Class Codes: A61K 39/464492 Glycoprotein 100 [Gp100]
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 16/3084 against tumour-associated gangliosides
• CPC Class Codes: C07K 2317/622 Single chain antibody (scFv)
• CPC Class Codes: C12N 5/0638 Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]

Abstract

The present invention concerns immunotherapy for cancers having cells that comprise the ganglioside GD2 antigen. In specific embodiment, T cells having a chimeric receptor that targets GD2 is employed. In particular cases, the chimeric receptor comprises antibody, cytoplasmic signaling domain from the T cell receptor, and/or costimulatory molecule(s).

Claims

1. A method of targeting a cancer cell having a GD2 antigen, comprising the steps of providing to the cell a cytotoxic T lymphocyte with a chimeric receptor that recognizes the GD2 antigen.

2. The method of claim 1, wherein the cancer cell is in vitro or in vivo.

3. The method of claim 1, wherein the chimeric receptor comprises antibody that binds GD2

4. The method of claim 2, wherein the antibody is a scFv antibody.

5. The method of claim 2, wherein the antibody is the 14g2a scFv antibody.

6. The method of claim 1, wherein the chimeric receptor comprises the effector domain of the T-cell receptor zeta chain or related signal transduction endodomains derived from the T cell receptor.

7. The method of claim 1, wherein the chimeric receptor comprises one or more costimulatory molecules.

8. The method of claim 6, wherein the costimulatory molecules comprise CD28, OX40, 4-1BB, or a combination thereof.

9. The method of claim 1, wherein the cancer cell is in an individual with melanoma or non small cell lung cancer.

10. A method of treating melanoma or non small cell lung cancer in an individual, comprising the steps of administering to an individual cytotoxic T lymphocytes having a chimeric receptor that recognizes a GD2 antigen on the surface of cancer cells.

11. The method of claim 10, wherein the chimeric receptor comprises antibody that binds GD2

12. The method of claim 11, wherein the antibody is a scFv antibody.

13. The method of claim 11, wherein the antibody is the 14g2a scFv antibody.

14. The method of claim 10, wherein the chimeric receptor comprises the effector domain of the T-cell receptor zeta chain.

15. The method of claim 10, wherein the chimeric receptor comprises one or more costimulatory molecules.

16. The method of claim 15, wherein the costimulatory molecules comprise CD28, OX40, 4-1BB, or a combination thereof.

17. The method of claim 10, wherein the individual has had and/or is having an additional cancer therapy for the respective melanoma or non small cell lung cancer.